Human mesenchymal stromal cells improve scar thickness without enhancing cardiac function in a chronic ischaemic heart failure model

Interactive Cardiovascular and Thoracic Surgery

Volumn 14, Issue 5, 2012, Pages 516-520

  Dayan, Victor ^a   Yannarelli, Gustavo ^a   Filomeno, Paola ^a   Keating, Armand ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cell transplantation; Myocardial infarction; Myocardial remodelling; Stem cells

Indexed keywords

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL DENSITY; CELL DIFFERENTIATION; CHIMERA; CHRONIC DISEASE; CHRONIC ISCHEMIC HEART FAILURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; GENE SEQUENCE; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICULAR END DIASTOLIC DIAMETER; HEART LEFT VENTRICULAR END SYSTOLIC DIAMETER; HEART MUSCLE; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; HEART VENTRICLE WALL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYME CELL; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCAR FORMATION; SCID MOUSE; STROMA CELL; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; CHRONIC DISEASE; CICATRIX; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATION; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84863466611     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivs048     Document Type: Article

References (15)

1. Dayan V, Yannarelli G, Billia F, Filomeno P, Wang XH, Davies JE et al. Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res Cardiol 2011;106:1299-310, doi: 10.1007/s00395-011-0221-9.
2. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009;54:2277-86.
3. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.1.
4. Khan M, Mohsin S, Khan SN, Riazuddin S.: Repair of senescent myocardium by mesenchymal stem cells is dependent on the age of donor mice. J Cell Mol Med doi: 10.1111/j.1582-4934.2009.00998.
5. Fukushima S, Varela-Carver A, Coppen SR, Yamahara K, Felkin LE, Lee J et al. Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 2007;115:2254-61.
6. van der Bogt KE, Schrepfer S, Yu J, Sheikh AY, Hoyt G, Govaert JA et al. Comparison of transplantation of adipose tissue- and bone marrowderived mesenchymal stem cells in the infarcted heart. Transplantation 2009;87:642-52.
7. McBride C, Gaupp D, Phinney DG. Quantifying levels of transplanted murine and human mesenchymal stem cells in vivo by real-time PCR. Cytotherapy 2003;5:7-18.
8. Marketou M, Kintsurashvili E, Papanicolaou KN, Lucero HA, Gavras I, Gavras H. Cardioprotective effects of a selective B(2) receptor agonist of Bradykinin post-acute myocardial infarct. Am J Hypertens 2010;23: 562-8.
9. Rose RA, Jiang H, Wang X, Helke S, Tsoporis JN, Gong N et al. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells 2008;26:2884-92.
10. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003;5:485-9.
11. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J 2009;30:2722-32.
12. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JEValdes D et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA 2009;106:14022-7.
13. Bartunek J, Croissant JD, Wijns W, Gofflot S, de Lavareille A, Vanderheyden M et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol 2007; 292:H1092-104.
14. Xu RX, Chen X, Chen JH, Han Y, Han BM.: Mesenchymal stem cells promote cardiomyocyte hypertrophy in vitro through hypoxia-induced paracrine mechanisms. Clin Exp Pharmacol Physiol 2009;36:176-80.
15. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 2003;107:618-25.